A carregar...
Publicação
Deca pharmaceuticals: fighting fungal infections with organometallic compounds, Iinnovation´s overview and ecosystem mapping
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 426.7 KB | Adobe PDF |
Orientador(es)
Resumo(s)
To better comprehend who can benefact from the value of an innovation, the entrepreneur
should acquire knowledge about the topic, as well as identifying all potential partners in a value
chain, to obtain valuable insights and progress faster.
Xaniglucan is the first product from Deca Pharmaceuticals, aimed to cure resistant C. glabrata
infections. Leveraging on the product’s characteristics and by relying on IP protection, the team
can hope to validate assumptions with the stakeholders identified to develop the drug into later
stages of clinical trials.
The entrepreneur now understands who plays a key role in different stages of development.
Descrição
Palavras-chave
Innovation Patent Stakeholder Invasive fungal infection C. glabrata Pharmaceutical company R&D Caffeine Nickel Mode of action Organometallic chemistry Esg